Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors

Journal of Clinical Oncology

Volumn 16, Issue 12, 1998, Pages 3858-3865

  Saltz, Leonard B ^a   Spriggs, David ^a   Schaaf, Larry J ^a   Schwartz, Gary K ^a   Ilson, David ^a   Kemeny, Nancy ^a   Kanowitz, Jane ^a   Steger, Carolyn ^a   Eng, Michael ^a   Albanese, Patricia ^a   Semple, Deborah ^a   Hanover, Cristy K ^a   Elfring, Gary L ^a   Miller, Langdon L ^a   Kelsen, David ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CISPLATIN; GLUCURONIDE; IRINOTECAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG RESISTANCE; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT OUTCOME;

EID: 0032407409     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.12.3858     Document Type: Article

References (34)

1. Fukuoka M, Niitani H, Suzuki A, et al: A phase II study of irinotecan, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 10:16-20, 1992
2. Masuda N, Fukuoka M, Kusunoki Y, et al: Irinotecan: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229, 1992
3. Takeuchi S, Noda K, Yakushiji M, et al: Late phase II study of irinotecan, topoisomerase I inhibitor, in advanced cervical carcinoma. Proc Am Soc Clin Oncol 11:224, 1992 (abstr)
4. Shimada Y, Yoshino M, Wakui A, et al: Phase II study of irinotecan, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 11:909-913, 1993
5. Rothenberg ML, Eckert JR, Kuhn JG, et al: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14:1128-1135, 1996
6. Conti JA, Kemeny NE, Saltz, LB, et al: Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14:709-715, 1996
7. Hsiang YH, Hertzberg R, Hecht S, et al: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873-14878, 1985
8. Hsiang YH, Liu LF: Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722-1726, 1988
9. Hsiang YH, Lihou M, Liu LF: Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49:5077-5082, 1989
10. Hertzberg RP, Caranfa MJ, Hecht SM: On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex. Biochemistry 28:4629-4638, 1989
11. Liu LF: DNA topoisomerases: Enzymes that catalize the breaking and rejoining of DNA. Crit Rev Biochem 15:1-24, 1983
12. Wang JC: DNA topoisomersases. Ann Rev Biochem 54:665-697, 1985
13. Cvitkovic E, Droz JP, Kattan J, et al: Cisplatin, in Citkovic E, Droz JP, Armand JP, et al (eds): Handbook of Chemotherapy in Clinical Oncology (ed 2). Jersey, Channel Islands, Scientific Communication International, 1993, pp 242-245
14. Muggia FM: Cisplatin update. Semm Oncol 18:1-4, 1991 (suppl 3)
15. O'Dwyer PJ, Johnson SW, Hamilton TC: Cisplatin and its analogues, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principals and Practice of Oncology. Philadelphia, PA, Lippincott Raven, 1997, pp 418-432
16. Eastman A: The formation, isolation, and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther 37:155-166, 1987
17. Rusch V, Saltz L, Ginsberg R, et al: A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol 12:1156-1163, 1994
18. NCI Common Toxicity Criteria. Bethesda, MD, National Cancer Institute, Division of Cancer Treatment, 1988
19. Miller AB, Hoogstrated B, Staquet M: Reporting of cancer treatment. Cancer 47:207-214, 1981
20. Gibaldi M, Perrier D: Pharmacokinetics, (ed 2). New York, NY, Marcel Dekker, 1982
21. Kano Y, Suzuki K, Akutsu M, et al: Effects of irinotecan in combination with other anticancer agents in culture. Int J Cancer 50:604-610, 1992
22. Fukuoka M, Kudoh S, Masuda N, et al: Synergistic effects of irinotecan and cisplatin or etoposide on human lung cancer cell lines and xenografts in nude mice. Proc Am Assoc Cancer Res 33:226, 1992 (abstr)
23. Fravel HN, Roberts JJ: Excision repair of cisdiaminedichloroplatinum (II)-induced damage to DNA of Chinese hamster ovary cells. Cancer Res 39:1793-1799, 1979
24. Plooy AC, van Dijk M, Berends F, et al: Formation and repair of DNA interstrand cross-links in relation to cytotoxicity and unscheduled DNA synthesis induced in control and mutant human cells treated with cisdiaminedichroloplatinum (II). Cancer Res 45:478-483, 1985
25. Gedick CM, Collins AR: Comparison of the effects of fostriecin, novo-biocin and camptothecin, inhibitors of DNA topo-isomerases, on DNA replication and repair in human cells. Nucleic Acid Res 18:1007-1014, 1990
26. Masumoto N, Nakano S, Esaki T, et al: Inhibition of cisdiaminodichloroplatinum (II)-induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous-carcinoma cells. Int J Cancer 62:70-75, 1995
27. American Society of Clinical Oncology: Recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol 12:2471-2508, 1994
28. Pitot HC, Wender DB, O'Connell MJ, et al: Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 15:2910-2919, 1997
29. Masuda N, Fukuoka M, Takada M, et al: Irinotecan in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 10:1775-1780, 1992
30. Masuda N, Fukuoka M, Kudoh S, et al: Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small cell lung cancer. J Clin Oncol 12:90-96, 1994
31. DeVore R, Crawford J, Dimery I, et al: Phase II trial of irinotecan plus cisplatin in advanced NSCLC. Proc Am Soc Clin Oncol 15:1674, 1997 (abstr)
32. Shirao K, Shimada Y, Kondo H, et al: Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 15:921-927, 1997
33. Masuda N, Fukuoka M, Kudoh S, et al: Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br J Cancer 68:777-782, 1993
34. Negoro S, Fukuoka M, Masuda N, et al: Phase I study of weekly intravenous infusions of irinotecan, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 83:1164-1168, 1991